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The global healthcare landscape is experiencing a shift with an increasing demand for 
decentralized testing. Diagnostic testing is moving from the benchtop to the bedside 
and there is a need for translational medical tools to help usher in the generation of 
personalized medicine. Point-of-care medical devices have become a powerful tool to 
help address this growing need and can help deliver high-quality diagnostic testing at 
lower costs and greater convenience in comparison to conventional laboratory 
techniques. Point-of-care devices have also emerged as a suitable platform for use in 
resource limited settings where access to state-of-the-art medical equipment is scarce. 
In this dissertation, I detail the design and development of three unique biomedical 
technologies: Nutriphone, H.E.R.M.E.S and cAST. These technologies were created 
and developed with the specific intention of advancing diagnostic testing at the point-
of-care with extended application for use in resource-limited environments. While 
there are similar themes in the design philosophy of the three technologies, they 
address entirely different areas of interest; Nutriphone enables rapid assessment of 
Vitamin D deficiencies, H.E.R.M.E.S enables quick and efficient pre-diagnostic 
sample preparation for blood-based testing and cAST offers accelerated assessment of 
antimicrobial resistance in bacterial organisms. I will highlight the underlying 
technical principles and the key innovations that we were able to demonstrate along 
with initial clinical results that make them promising platforms worthy of further 
development.  
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CHAPTER ONE 
 
INTRODUCTION 
1.1 Overview 
 
Personalized medicine is the future of healthcare. The demand for diagnostic testing is 
moving away from large established institutions like hospitals and closer to the home.  
To address this growing demand, diagnostic technologies must translate from the 
benchtop to the bedside and adapt to be suitable for use in low-complexity testing 
environments. Over the past two decades, this movement has been broadly classified as 
“Point-of-care” testing and has become the central idea around which medical 
technologies have started to evolve around. Point-of-care testing (POC) can help deliver 
high-quality diagnostic testing at lower costs and greater convenience in comparison to 
conventional laboratory method.  Further, POC testing represents a suitable platform 
that can elevate testing standard standards in resource limited settings where access to 
state-of-the-art medical equipment is scarce. 
 In this dissertation, I detail the design and development of three unique 
biomedical technologies that are appropriate for use at the point-of-care: Nutriphone 
H.E.R.M.E.S and cAST. I dedicate each chapter of my thesis to one of each of the 
above-mentioned technologies. These technologies were designed with the specific 
intention of being limited-resource friendly and while there are similar themes in the 
design philosophy, each technology addresses an entirely different area of interest. I will 
first discuss the Nutriphone, which was designed for the rapid assessment of Vitamin D 
deficiencies in blood. Then I will detail my invention, H.E.R.M.E.S, which is a unique 
alternative to perform quick and efficient pre-diagnostic sample preparation for blood-
based testing. Finally, I will detail cAST, a platform we developed that offers 
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accelerated assessment of antimicrobial resistance in bacterial organisms. In each case, 
we validated the technologies with relevant samples in order to further cement their 
applicability for use in translational medical environments.  
 
1.2 A quantitative assay for the assessment of Vitamin D3 deficiencies 
 
Chapter 2 of this dissertation elaborates on the development and validation of a rapid 
diagnostic test for the assessment of Vitamin D deficiencies. Vitamin D is necessary for 
the healthy growth and development of bone and muscle. Vitamin D deficiency, which 
is present in 42% of the US population, is often undiagnosed as symptoms may not 
manifest for several years and long-term deficiency has been linked to osteoporosis, 
diabetes and cancer. Currently the majority of vitamin D testing is performed in large-
scale commercial laboratories which have high operational costs and long times-to-
result. Development of a low-cost point-of-need assay could be transformative to 
deficiency analysis in limited-resource settings. The best biomarker of vitamin D status, 
25hydroxyvitamin D3 (25(OH)D3), however, is particularly challenging to measure in 
such a format due to complexities involved in sample preparation, including the need to 
separate the marker from its binding protein. In this chapter, we present a rapid 
diagnostic test for the accurate, quantitative assessment of 25(OH)D3 in finger-stick 
blood. The assay is accompanied by a smartphone-assisted portable imaging device that 
can autonomously perform the necessary image processing. To achieve accurate 
quantification of 25(OH)D3, we also demonstrate a novel elution buffer that separates 
25(OH)D3 from its binding protein in situ, eliminating the need for sample preparation. 
We highlight the validation of the assay with human serum and blood samples. In human 
trials, the accuracy of our platform is 90.5%. 
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1.3 Development of a magnetic bead-based blood-plasma separation 
system 
 
In Chapter 3, I detail the design and development of the High Efficiency Rapid Magnetic 
Erythrocyte Separator (H.E.R.M.E.S), a rapid low-cost technology that can perform the 
separation of red blood cells from plasma at a fraction of the time and cost of that of a 
centrifuge. H.E.R.M.E.S was designed to help blood-testing cope with the increasing 
demand for CLIA-waived testing facilities that offer diagnostic capabilities at lower 
costs and greater convenience than traditional laboratory testing. While several new 
diagnostic tools have emerged to fulfill testing requirements in these environments, 
centrifuges have been stymied from transitioning to the point-of-need as the US Food 
and Drug Administration (FDA) classifies them as mostly unsuitable for use in CLIA-
waived environments. Limitations in sample processing capabilities adversely affects 
the ability for CLIA-waived testing environments to offer a broad testing portfolio and 
present-day diagnostics are bottlenecked by the requirement for centrifugation. 
H.E.R.M.E.S is a unique method to perform rapid, low-cost sample processing and can 
perform the separation of red blood cells from plasma at a fraction of the time and cost 
of that of a centrifuge. In Chapter 2, we demonstrate that H.E.R.M.E.S is able to obtain 
highly-pure plasma (greater than 99.9% purity) at less than 2 minutes per test. 
H.E.R.M.E.S was originally designed for use with rapid diagnostic tests such as lateral 
flow assays, however, through the development of the technology, we discovered that 
it is capable of being incorporated with any present-day diagnostic technology. We also 
prove that it is superior to existing alternatives to centrifugation by validation with a 
ferritin lateral flow test.  
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1.4 A novel approach for the detection of antimicrobial resistance in 
bacteria 
 
In the final chapter, I discuss our initial efforts at developing a detection platform for 
the rapid assessment of antimicrobial resistance in infectious bacterial organisms. 
Antibiotic resistance is a major global health concern due to an overuse of antibiotics in 
medicine and in agriculture. It is estimated that by 2050, 10 million people will die from 
antibiotic resistant bacteria. For patients with septic shock, it is estimated that for every 
hour that effective antibiotic treatment is delayed, the survival rate drops by 7.6%. There 
is a need for effective diagnostic tools that can enable rapid and accurate assessment of 
antibiotic resistance in order to facilitate the immediate application of appropriate 
antibiotic therapy. This is of particular importance for resource-limited settings where 
access to state-of-the-art treatment and equipment is limited. We describe the design of 
cAST, a unique approach that offers accelerated assessment of antibiotic resistance. 
cAST uses a capillary form factor that enhances the growth rate of the bacterial cells, 
thereby expediting the time to readout. Further, cAST was built using a combination of 
off-the-shelf parts and custom 3D printed holders to enable low-cost, real-time 
assessment of bacterial viability with the help of a portable spectrometer. We first 
demonstrate that capillary incubation is superior to standard bacterial growth in a well 
and then detail the validation of our platform with 5 different clinically relevant 
infectious organisms. We demonstrate detection of bacterial growth within 4-8 hours 
and detail the future work that can be done in order to further improve the design of 
cAST. The underlying technology of cAST makes it immediately applicable to existing 
clinical methods used to determine AST and can be further simplified for qualitative use 
in resource-limited settings.  
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CHAPTER 2 
 
A QUANTITATIVE POINT-OF-NEED ASSAY FOR THE ASSESSMENT OF 
VITAMIN D3 DEFICIENCY
† 
 
2.1 Abstract 
 
Vitamin D is necessary for the healthy growth and development of bone and muscle. 
Vitamin D deficiency, which is present in 42% of the US population, is often 
undiagnosed as symptoms may not manifest for several years and long-term deficiency 
has been linked to osteoporosis, diabetes and cancer. Currently the majority of vitamin 
D testing is performed in large-scale commercial laboratories which have high 
operational costs and long times-to-result. Development of a low-cost point-of-need 
assay could be transformative to deficiency analysis in limited-resource settings. The 
best biomarker of vitamin D status, 25hydroxyvitamin D3 (25(OH)D3), however, is 
particularly challenging to measure in such a format due to complexities involved in 
sample preparation, including the need to separate the marker from its binding protein. 
Here we present a rapid diagnostic test for the accurate, quantitative assessment of 
25(OH)D3 in finger-stick blood. The assay is accompanied by a smartphone-assisted 
portable imaging device that can autonomously perform the necessary image 
processing. To achieve accurate quantification of 25(OH)D3, we also demonstrate a 
novel elution buffer that separates 25(OH)D3 from its binding protein in situ, 
eliminating the need for sample preparation. In human trials, the accuracy of our 
platform is 90.5%. 
†Reprinted with permission from Vemulapati, S., Rey, E., O’Dell, D., Mehta, S., and Erickson, D. 
Scientific Reports 7 (2017). 
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2.2 Introduction 
 
Vitamin D refers to a group of fat soluble secosteroids responsible for promoting 
absorption of calcium, phosphate and zinc in the body1,2. It is also essential for the 
healthy growth and maintenance of bone and muscle3. Vitamin D deficiency causes 
rickets in children4 and low levels of vitamin D have been attributed to diabetes, heart 
disease, cancer and osteoporosis in adults5. Vitamin D is also critical for ensuring 
optimal immune function; for example, vitamin D is required for producing 
antimicrobial peptides such as cathelicidin, necessary to combat pathogens such as 
Mycobacterium tuberculosis in human macrophages6. Deficiency is defined by 
evaluating the serum concentrations of 25-hydroxyvitamin D, or 25(OH)D, a pro-
hormone that is produced in the liver by hydroxylation of cholecalciferol, the 
biologically inert form of vitamin D that is produced in the skin. 25(OH)D is the major 
circulating form of vitamin D and is considered the best indicator of holistic vitamin D 
status. Supplemental vitamin D is available in two forms: ergocalciferol (vitamin D2) 
and cholecalciferol (vitamin D3). Even though commonly prescribed supplements 
contain either vitamin D2 or vitamin D3, it has been demonstrated that cholecalciferol 
has a higher efficacy at raising the total serum 25(OH)D status in individuals7,8. As a 
result, many of the supplements now on the market contain cholecalciferol. The 
Endocrine Society guidelines suggest that individuals with serum concentration of 
25(OH)D greater than 75 nmol/L can be considered healthy while those with values 
between 50 and 75 nmol/L are insufficient and lower than 50 nmol/L are deficient9. 
In the United States, the prevalence of vitamin D deficiency rate is estimated at 42%, 
with a higher incidence amongst the African American (82%) and Hispanic (69%) 
population10. Deficiency can be corrected with supplementation and dietary changes 
particularly when detected early; however, many people are unaware of their status due 
to the lack of easy to access methods for quantifying 25(OH)D3 levels in human serum. 
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Point-of-care vitamin D deficiency testing remains a significant challenge due to the 
presence of vitamin D binding protein, a carrier protein that helps transport 25(OH)D in 
blood. 95-99% of available 25(OH)D in blood is bound to vitamin D binding protein11,12 
and due to the nature of the strong hydrophobic bond between them, it is not possible to 
assess an individual’s vitamin D status without separating the two from each other. 
Furthermore, vitamin D binding protein is always present in significant molar excess in 
blood and has no correlation with the amount of circulating 25(OH)D13–15. As a result, 
it cannot be used as a target itself, a scheme which has been adopted for targets such as 
vitamin A16–19.  
Current clinical methods for quantitation of 25(OH)D can be broadly divided into 
chromatographic methods with (LC/MS-MS: Liquid Chromatography Tandem Mass 
Spectrometry) and without (HPLC: High Performance Liquid Chromatography) mass 
spectrometric detection and competitive immunoassays such as RadioImmunoAssay 
(RIA). These techniques are expensive and time consuming due to the need for 
specialized equipment and personnel and the necessity to separate and remove vitamin 
D binding protein presents further complications by requiring elaborate sample 
preparation. Usually the sample is treated and incubated (for ~1 hour) with large 
amounts of organic solvents such as acetonitrile to perform the separation step. Further, 
organic solvents cannot be used directly with blood as they cause lysis of blood cells, 
and require that the blood be centrifuged into serum. Standard protocols also require an 
additional centrifugation step after the organic solvents are added in order to remove the 
precipitated protein. These tedious sample preparation requirements combined with the 
need for specialized equipment pose a severe limitation for the development of point-
of-need tests for the assessment of vitamin D status.  
In recent years, several research groups have employed microfluidic techniques to 
develop low cost methods to assess micronutrient status at the point-of-need. A 
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microfluidic chip that was able to perform the detection of ferritin and CRP in human 
serum samples was demonstrated by Kartalov et al20. Similarly, Dimov et al exhibited 
the “stand-alone self-powered integrated microfluidic blood analysis system 
(SIMBAS)” for detection of vitamin B621. While these works have demonstrated 
excellent proof of concepts for use at the point of care, they are limited by their inability 
to perform blood processing on chip and the need for expensive imaging equipment. 
Lee et al.22 demonstrated the vitamin AuNP-based Immunoassay Device (vitaAID), a 
system for quantification of vitamin D levels using a smartphone. In that work, a novel 
gold nanoparticle-based immunoassay architecture was developed and analyzed by a 
smartphone camera, enabling quantification of serum samples without the need for 
expensive lab equipment. Even though the method helped transition vitamin D testing 
out of the lab, the technique was limited by its inability to perform blood processing on 
chip and non-trivial incubation time (~6 hours). 
In this work, we present a rapid diagnostic test that is capable of accurate, quantitative 
assessment of vitamin D status. Our test focuses on quantification of 25(OH)D3, the 
largest component of circulating 25(OH)D, in the deficient range (< 50nmol/L), as that 
is where the greatest need is. Quantitative ability is necessary in the deficient range to 
help distinguish between individuals who are severely and moderately deficient. In 
order to maintain compatibility with existing manufacturing techniques, we developed 
our diagnostic test as a lateral flow assay. Furthermore, our diagnostic test is integrated 
into a smartphone-assisted imaging platform which allows for easy operation and 
hassle-free access to test results. In addition to being capable of processing blood on 
strip, our test incorporates a novel elution buffer that is compatible with lateral flow 
assays to achieve separation of 25(OH)D3 from its binding protein in situ, eliminating 
the need for any sample preparation. We show reliable quantification of physiologically 
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relevant vitamin D3 levels in standard solutions, commercial calibrators, human serum 
and finger stick blood.  
 
2.3 Results 
 
2.3.1 Vitamin D3 diagnostic test protocol 
The system consists of a vitamin D3 diagnostic test, custom made cassette that houses 
the test and a portable reader (TIDBIT) (See Figure 1). The TIDBIT has been designed 
so that when the cassette is inserted into the device, it is aligned with a CMOS camera 
that automatically captures an image of the test area. The TIDBIT can be operated via a 
smartphone or computer application and can be controlled with the help of the 
Nutriphone application. Once the image is taken, a custom python script automatically 
crops the image and deduces the ratio of intensities of the test line to the control line, or 
T/C ratio (See Figure 2B and 2C). The T/C ratio is correlated to a value of 25(OH)D3 
by using a calibration curve, that is determined prior to testing by analyzing samples of 
known 25(OH)D3 values. 
To run a vitamin D3 test, the user starts the Nutriphone application on the device of 
choice and follows the instructions. First the user applies a small amount (4µL) of 
elution buffer on the edge of the sample pad. The user then collects 40µL of blood from 
a finger prick and places it onto the sample collection pad. After allowing for the blood 
to separate into serum and mix with the elution buffer, the user is prompted by the 
smartphone application to apply 15µL of running buffer for the filtered serum to enter 
the conjugate pad. After another short period of incubation, the user is again prompted 
to add 25 µL of running buffer to start the test. Following this step, the user must place 
the cassette in the TIDBIT, which automatically images and analyzes the test strip when 
the test and control lines are fully developed. Briefly, a grayscale image is taken using 
the TIDBIT and processed by a python script to filter out the noise using a Gaussian 
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filter. The noisy 2D image is filtered and converted to the grayscale, followed by a 
median filtering process to convert the 2D image into a 1D array, reducing the task to 
analyzing a 1D digital signal. The test and control lines of concentrated AuNP – anti 
25(OH)D3 are detected as local minima on the intensity plot. The respective peak values 
can be used to calculate a T/C ratio. 
 
 
Figure 1: Protocol for Vitamin D3 diagnostic test. The TIDBIT is depicted as the last image on the right. 
 
2.3.2 Design and implementation of a protein elution buffer:  
Vitamin D binding protein interferes with the capture and quantification of 25(OH)D3 
via traditional immunoassay techniques. Commercial tests such as the DiaSorin RIA 
call for mixing the sample with 10X the amount of acetonitrile, an organic solvent, in 
order to liberate all 25(OH)D3 in the sample from the binding protein
23. This method 
cannot be directly translated for application with a low-cost point-of-need lateral flow 
platform for several reasons. Firstly, organic solvents cause lysis of red blood cells24, 
making it unsuitable for use with blood samples; the sample must be first spun down 
into serum via centrifugation, a process that is difficult to perform in point-of-need 
settings. Secondly, if not neutralized or removed prior to running the test, acetonitrile 
could negatively affect the conjugated gold nanoparticles and the dispensed reagents on 
the test and control lines as the antibodies present are prone to denaturation themselves. 
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Finally, adding large amounts of organic solvent is particularly unsuitable for lateral 
flow platforms, as they may adsorb to the nitrocellulose membrane and alter its wetting 
properties 26. It was therefore necessary to develop an elution buffer that could denature 
binding protein in the sample without lysing blood cells while maintaining compatibility 
with the nitrocellulose membrane, the conjugated nanoparticles and the dispensed 
reagents.  
In order to perform the separation of 25(OH)D3 from its binding protein, our diagnostic 
test takes advantage of carefully optimized organic solvents and low pH buffers, which 
are known to be effective at denaturing proteins. After assessing a number of possible 
combinations, we decided on a combination of Dimethyl sulfoxide (DMSO), ethanol 
and a low pH acetate buffer. We hypothesize that DMSO and ethanol are able to unfold 
vitamin D binding protein while also serving as organic solvents to stabilize the 
liberated 25(OH)D3
25. This unfolding effect is further enhanced in the presence of a low 
pH buffer as most proteins undergo destabilization at low pH26. As seen in Figure 3B, 
there is no relationship between [25(OH)D3] and the T/C ratio when samples are tested 
for vitamin D3 without the use of any elution buffer.  
 
2.3.3 Vitamin D3 diagnostic test architecture and principles:  
The vitamin D3 diagnostic test seen in Figure 2 consists of a: blood filtration membrane, 
a conjugate pad that dry stores gold nanoparticle conjugates (AuNP – anti 25(OH)D3), 
a spacer pad that allows for incubation of the sample with the elution buffer and the 
conjugates, a nitrocellulose membrane that houses immobilized 25(OH)D3-BSA and 
secondary antibodies and a cellulose fiber absorbent pad respectively. When applicable, 
the blood filtration membrane can be substituted for a cellulose fiber pad to perform 
testing in human serum. Our test strip adopts a competitive type architecture as 
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25(OH)D3 is unable to bind to more than one antibody at a time due to its small size 
(~350 Daltons). 
The architecture of the diagnostic test was designed in order to prevent any need for 
specialized sample preparation. Prior to starting the test, the user dispenses a small 
amount of elution buffer onto the front edge of the blood filtration membrane to prevent 
the interaction of the elution buffer and the red blood cells present in the blood sample. 
Once the user dispenses the blood on the sample pad, it automatically flows forward 
through the filtration paper and separates into serum while simultaneously mixing with 
the elution buffer. This causes bound 25(OH)D3 to be released from the binding protein 
present in the sample. After the first instance of running buffer is applied, the sample 
enters the conjugated pad and the unbound 25(OH)D3 interacts with the AuNP-anti 
25(OH)D3 conjugates. This step is critical for the proper functioning of the assay. Based 
on the amount of 25(OH)D3 in the sample, there is a competitive interaction between 
the immobilized 25(OH)D3-BSA on the nitrocellulose and the 25(OH)D3 in the sample 
for binding sites on the AuNP-antibody conjugates as the sample flows through the 
nitrocellulose. As seen in Figure 2B, an individual with vitamin D3 deficiency will 
observe a T/C ratio that is high as most binding sites on the conjugates will be empty 
and free to bind to the immobilized 25(OH)D3.  Conversely, an individual with healthy 
levels of 25(OH)D3 will observe a T/C ratio that is low as most of the binding sites on 
the conjugates are occupied with 25(OH)D3 from the sample which prevents them from 
binding at the test line (Figure 2C).  
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Figure 2. Vitamin D3 Lateral Flow Assay. (A) Image and schematic of the 25(OH)D3 strip architecture 
and components. B) Image and intensity plot of a participant with low Vitamin D3 and high T/C ratio C) 
Image and intensity plot of a participant with healthy levels of 25(OH)D3 and low T/C ratio. 
 
Figure 3: Elution Buffer. A) Elution of 25(OH)D3 from binding protein with the help of organic solvents 
and low pH buffer and B) Calibration curve obtained from analyzing samples without the use of elution 
buffer. As seen, there is no relationship between [25(OH)D3] and [T/C] without the use of the elution 
buffer. 
 
2.3.4 25(OH)D3 quantification in standard solution and commercial calibrators:  
In Figure 4A, we demonstrate that the T/C ratio can be correlated to a 25(OH)D3 
concentration in standard solutions. At each concentration, two strips were used and the 
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maximum lower and upper deviations from the average T/C values were shown. The 
coefficient of variation of our assay ranges from 1.7% at 100 nmol/L to 14.7% at 125 
nmol/L. We then fitted a linear curve such that [25(OH)D3] = f(T/C). We also tested the 
performance our assay with standard solutions that were spiked with 25(OH)D2 in order 
to evaluate the cross-reactivity of the assay (inset in Fig. 4A). To verify the accuracy of 
the assay in serum, 25(OH)D3 levels were also quantified in commercially available 
serum-based standards (ChromSystems Inc). The calibrators are based on pooled human 
serum and contain artificially spiked values of 25(OH)D3 that lie in the physiologically 
relevant range. As seen in figure 4B, our assay is able to reliably distinguish between a 
deficient, insufficient and healthy sample. These standards did not require the use of the 
elution buffer as these samples were prepared by artificially introducing 25(OH)D3 into 
the sample. The coefficient of variation of our assay ranges from 2.63% at 85 nmol/L 
to 11.2% at 0 nmol/L.  
 
Figure 4: Calibration curve in standards. A) T/C ratios of the colorimetric signals at different 25(OH)D3 
concentration in standard buffers. T/C ratio = a[25(OH)D3]+b, where a=-0.0251 and b =3.983. Linear 
logistic curve was fitted with R2 = 0.95. The inset demonstrates a calibration curve performed with 
standard buffers that were spiked with 25(OH)D2 to verify cross-reactivity. A linear logistic curve was 
fitted with R2 = 0.0059 indicating no dependence of T/C ratio on [25(OH)D2]  B) T/C ratios of the 
colorimetrics signals at different 25(OH)D3 concentrations in commercial  serum based calibrators. T/C 
ratio= 𝑑 +
𝑎−𝑑
1+(
[25(𝑂𝐻)𝐷3]
𝑐
)𝑏
, where a = 2.81, b = 2.63, c = 26.2 and d = 1.52. A four-parameter logistic curve 
was fitted with R2 = 0.99. At each concentration two strips were used and the maximum and minimum 
deviation from the average is shown as error bars. 
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2.3.5 Vitamin D3 deficiency testing in human serum:  
Our assay was used to quantify the vitamin D3 levels in human serum samples that were 
collected from a human trial to demonstrate the assay’s applicability in the clinical 
setting (Fig 5A, 5B and 5C). Native serum samples required the use of elution buffer to 
separate 25(OH)D3 from vitamin D binding protein. As expected of our competitive 
type architecture, the T/C ratio for a participant with vitamin D deficiency appears to be 
significantly greater than that of a participant with vitamin D insufficiency. Actual 
serum 25(OH)D3 values were quantified using tandem liquid chromatography/mass 
spectrometry (LC/MS-MS). Figure 5B shows a ROC curve for the serum tests based on 
a linear calibration curve that was determined from the same batch of test strips (figure 
5A). We used the DeLong method27 to obtain an asymptotically exact method to 
evaluate the area under curve (auc) using 300,000 iterations with a cutoff of 50 nmol/L. 
A similar method was used to evaluate the performance of the assay at a cutoff of 30 
nmol/L28 that can be seen in Figure 5C. Diagnostic accuracy, defined as the proportion 
of correctly classified subjects to all subjects, was evaluated as 90.5% and 100% for the 
two cutoffs respectively. Both cutoffs are based on recommendations made by the 
Institute of Medicine. The root mean square error was assessed to be 5.4 nmol/L. The 
coefficient of variation ranged from 0.05% at 43 nmol/L to 16.6% at 57 nmol/L.  
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Figure 5: Analysis of human trial samples A) Linear calibration curve for 21 human serum samples with 
R2 = 0.91. T/C ratio = a[25(OH)D3]+b where a = -0.075 and b = 5.689 B) ROC curve obtained with 
Delong method with n=300000 and auc 0.836 at a cutoff of 50nmol/L C) ROC curve obtained from 
Delong method with n=300000 and auc 1 at a cutoff of 30 nmol/L D) Calibration curve from 6 human 
finger stick blood samples with R2 = 0.94. T/C ratio = a[25(OH)D3] + b where a = -0.033 and b = 2.9925. 
 
2.3.6 Vitamin D3 deficiency testing in finger prick blood samples:  
We used our assay to quantify vitamin D3 levels in finger prick blood from volunteers 
after obtaining informed consent, as per a protocol approved by the Institutional Review 
Board at Cornell University. Samples were run and analyzed at the site of the trial. 
Figure 5D demonstrates a calibration curve for the sample set with R2 value of 0.94. 
From figure 5D, it is apparent that our assay demonstrates a linear correlation between 
the T/C ratio and [25(OH)D3]. Additionally, by observing the change in T/C ratio, we 
are able to demonstrate that our test can distinguish between a severely deficient, 
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deficient and insufficient participant with reasonable certainty. The coefficient of 
variation ranged from 0.5% at 39 nmol/L to 17.2% at 48 nmol/L.  
 
2.4 Discussion 
 
In this work, we demonstrate a rapid and easy to use microfluidic platform for the 
assessment of vitamin D status. We showed the quantification of 25(OH)D3 in the 
physiologically relevant range within minutes. This was achieved by using a 
competitive type lateral flow assay that incorporates a novel elution buffer which 
separates 25(OH)D3 from its binding protein on the strip, therefore eliminating the need 
for tedious sample preparation. The assay produces a colorimetric image that can be 
analyzed to obtain a T/C ratio that can be correlated to a concentration of 25(OH)D3 in 
the sample (serum or blood). We further validate the system by quantifying levels in 
trivial amounts of human serum and a finger prick of blood. Given the limitations of 
traditional clinical diagnostic methods, our assay has the potential to make an immediate 
impact in the point-of-need setting as an accurate tool for the assessment of vitamin D3 
status.  
Our work presented here is the first quantitative, point-of-need diagnostic test for the 
assessment of vitamin D3 status and represents a critical step towards transitioning 
vitamin D deficiency testing out of the lab and into the hands of individuals. Unlike 
commercial platforms that have been developed for micronutrient testing, our test is 
able to process finger stick blood, denature vitamin D binding protein in situ and 
quantify levels of 25(OH)D3 in the sample in a few minutes without the need for 
expensive equipment. These unique traits coupled with a high diagnostic accuracy 
(90.5%) make our test sufficient for application at the point of need. Our assay is 
designed specifically for assessing 25(OH)D3 status in the deficient range (< 50 nmol/L) 
as this is where differentiation is most important. However, we have also demonstrated 
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that our test is able to reliably quantify concentrations in the complete physiologically 
relevant range (0 – 150nmol/L). Since our assay is unable to detect 25(OH)D2, the 
quantitative ability is limited when used in settings where ergocalciferol is the preferred 
supplement. However, the recent uptake in vitamin D3 supplementation suggests that 
our diagnostic test is practical for use in many point-of-need settings29,30. Given the 
minimal amount of expertise needed to run the assay, our test enables individuals to 
evaluate their own vitamin D status irrespective of their medical training or knowledge. 
The low cost and portability of the testing platform will also make monitoring and 
evaluation of the efficacy of nutrition interventions feasible in both research and 
programmatic settings. Furthermore, we have developed a protein elution buffer that 
could be adopted to improve several other diagnostic tests that require specialized 
sample preparation because of the presence of a binding protein (vitamins A, B7 and 
B12).  
 
2.5 Materials and Methods: 
 
2.5.1 Gold Nanoparticle Conjugation 
The monoclonal anti-25(OH)D3 IgG produced in mouse (GenScript Inc) was conjugated 
with 40nm Gold Nanoparticles using the InnovaCoat Gold Conjugation Kit (Innova 
Biosciences Ltd). For the conjugation, 0.23µg AuNP in freeze dried form was mixed 
with 1ug anti 25(OH)D3 IgG in 0.01 M amine free phosphate buffer saline at pH 7.4. 
The anti-25(OH)D3 IgG is attached to the surface of AuNP via lysine residues during a 
15-minute incubation and the reaction was terminated by adding 0.1M tris-buffered 
saline (TBS) with 0.1 % Tween 20. To remove excess antibodies, DI water was added 
in 10 times the volume of the conjugate mixture as centrifuged at 9000 g for 10min. 
Upon removal of the supernatant, the final gold nanoparticle concentration was 
reconstituted in 0.01M TBS containing 2% BSA and the final optical density was 
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verified by using Spectramax 384 to measure absorbance of the conjugates at a 
wavelength of 530 nm. The conjugates were stored at 4ºC until use. Conjugate pads 
were prepared by first diluting the conjugates to roughly 0.7 – 0.8 OD (depending on 
application) in a conjugate buffer (2mM Borate buffer with 5% sucrose) which 
contained appropriate preservatives. Glass Fiber conjugate pads (EMD Millipore) with 
30cmx5cm dimensions were soaked in diluted conjugate solution for 2 minutes 
followed by drying at 37 ºC for a minimum of 12h.  
 
2.5.2 Vitamin D3 lateral flow assay preparation:  
Hi Flow Plus 180 membrane Cards (EMD Milipore) were used as the assay platform. 
The membrane cards have a 2mm clear polyester film backing that contains the 
nitrocellulose membrane and the adhesive that allows for assembly of conjugate and 
sample pads. The nitrocellulose part of the assay extends for 2.5 cm in length and has a 
nominal capillary flowrate of 45 seconds/cm. This is the slowest flow rate offered by 
the manufacturers and was chosen to allow for maximum reaction time between the 
sample and the conjugates due to the relatively low detection range. The test and control 
lines were prepared by using a Lateral Flow Reagent Dispenser (Claremont Bio) to 
dispense 0.4mg/mL of anti-mouse IgG produced in goat and 1mg/mL of 25(OH)D3-
BSA. The two lines are separated by 3mm and have line widths of 1mm. These lines 
were dispensed using the Legato 200 Dual Syringe Pump (Claremont Bio) at 6.7µL/min. 
Once the reagents were dispensed, they were dried for a minimum of 12 hours at 37ºC. 
The final assay was assembled by first applying the spacer pad onto the bottom of the 
nitrocellulose portion with 2-3mm overlap followed by a dried conjugate pad. The 
sample pad, which is the final component, varies based on the sample that is to be tested. 
Cellulose pads (EMD Milipore) were used for serum samples and FR1 blood filtration 
membranes (MDI membrane technologies) were used for blood samples. In both cases, 
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the sample pad was attached below the conjugate pad with 2mm overlap. The FR-1 
membrane has a thickness of 0.35 mm and capacity of 30µL/cm2 and measured to be 30 
cm x 2.5cm while the Cellulose pad measured to be 30cm x 1cm. Another cellulose 
fiber sample pad was attached at the top of the nitrocellulose card to serve as an 
absorbent pad to collect any waste from the assay. The assembled assay was then cut 
into 4mm strips using a rotary paper trimmer. The strips were then kept sealed in a 
plastic container and wrapped in aluminum foil in a humidity controlled chamber 
(Secador) for a few days to prevent adverse effects of exposure to varying temperature 
and humidity. Test strips remain integral for up to several weeks while stored in these 
conditions. However, their shelf life can be extended up to a year if they are sealed in 
light safe mylar pouches and stored at room temperature.  
 
2.5.3 Elution buffer preparation: 
 A combination of organic solvents and low pH buffers was used to ensure the 
separation of vitamin D binding protein and 25(OH)D3 on strip. We mixed 4.7 parts of 
1:1 mixture of Dimethyl sulfoxide (VWR) and Pure Ethanol (Acros Organics) with 1 
part of pH 4.0 acetate buffer (VWR). In the case of finger prick blood testing, 4µL of 
this mixed buffer was added to the area of overlap between the blood filtration 
membrane and the conjugate pad to allow for the filtered serum to interact with the 
elution buffer prior to the reaction with the conjugates. Elution buffer cannot be added 
directly to whole blood as the organic solvents cause lysing of blood cells. As for serum, 
the same amount of elution buffer was mixed in with the sample in a plastic 1.5 mL 
micro-centrifuge vial prior to applying the sample to the strip.  
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2.5.4 Vitamin D3 test strip protocol and human trials:  
Capillary tubes were used for the collection of constant amount of blood from the 
participants. First, 4µL of elution buffer was pipetted onto the area of overlap between 
the sample pad and the conjugate pad. This allows for the filtered serum to interact with 
the elution buffer prior to the conjugates. Elution buffer is added prior to the interaction 
of the sample with the AuNP-anti 25(OH)D3 conjugates to avoid affecting the 
performance of the gold nanoparticles. Nanoparticle aggregation was observed when 
the conjugates are mixed directly with elution buffer. Additionally, adding elution 
buffer to the sample prior to incubation reduces the adverse effects of the elution buffer 
on the conjugates. After allowing for 4 minutes for the sample to filter into serum, 15 
µL of running buffer is added to flow the sample and elution buffer mixture into the 
conjugate pad. After allowing for an additional four minutes of incubation, 25 µL of 
running buffer is added to start the flow onto the nitrocellulose membrane. At this point, 
the user inserts the cartridge into the imaging device. The imaging device automatically 
images the diagnostic test when the test and control lines are fully developed.  
The human trials were approved by the Institutional Review Board for Human Subjects 
at Cornell University and carried out in accordance with their regulations. Informed 
consent was obtained from all participants prior to testing. For the trial, the participants 
were subjected to a finger prick (UniStik) for a drop of blood which was collected using 
a capillary tube and dispensed onto the sample pad. A trained and certified phlebotomist 
then drew 5mL of blood via venipuncture which was used for tandem mass spectrometry 
analysis. Following 1-hour incubation at room temperature, serum was separated by 
centrifugation at 2000 g for 10 min. Serum 25(OH)D levels were characterized using 
tandem mass spectrometry (LC/MS-MS). 
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2.5.5 TIDBIT and image processing:  
Test strips were imaged using a portable imaging device designed specifically for 
colorimetric detection and quantification. The device consists of a 5-megapixel 1080p 
HD CMOS camera (Rasbperry Pi), focusing lens and LEDs (Thorlabs Inc), raspberry 
Pi computer board, rechargeable lithium ion battery pack (Adafruit Industries) and slide 
out cassette tray, all surrounded by a 3D printed light tight container. Once the cassette 
is inserted into the imaging device, it is automatically imaged and processed using a 
custom python script. 
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CHAPTER 3 
 
H.E.R.M.E.S: RAPID BLOOD-PLASMA SEPARATION AT THE POINT-OF-
NEED* 
 
3.1 Abstract 
 
The global healthcare landscape is experiencing increasing demand for CLIA-waived 
testing facilities that offer diagnostic capabilities at lower costs and greater convenience 
than traditional laboratory testing. While several new diagnostic tools have emerged to 
fulfill testing requirements in these environments, centrifuges have been stymied from 
transitioning to the point-of-need as the US Food and Drug Administration (FDA) 
classifies them as mostly unsuitable for use in CLIA-waived environments. Limitations 
in sample processing capabilities adversely affects the ability for CLIA-waived testing 
environments to offer a broad testing portfolio and present-day diagnostics are 
bottlenecked by the requirement for centrifugation. Here we present the High Efficiency 
Rapid Magnetic Erythrocyte Separator (H.E.R.M.E.S), a rapid low-cost technology that 
can perform the separation of red blood cells from plasma at a fraction of the time and 
cost of that of a centrifuge. We demonstrate that H.E.R.M.E.S is able to obtain highly-
pure plasma (greater than 99.9% purity) at less than 2 minutes per test. Further, we detail 
that it is an easy-to-use method capable of being incorporated with present-day 
diagnostic technologies and prove that it is superior to existing alternatives to 
centrifugation by validation with a ferritin lateral flow test. H.E.R.M.E.S is a suitable 1  
alternative for centrifugation in point-of-need settings and aims to facilitate the 
decentralization of commercial blood testing 
*Reprinted with permission from Vemulapati, S. and Erickson, D. Lab on a Chip 18, 3285–3292 (2018). 
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3.2 Introduction 
 
The US blood testing market is estimated at $20 billion and is expected to increase to 
$30 billion by 203029.  This predicted growth stems from an increasing demand for 
CLIA-waived testing environments, such as Urgent Care and Minute Clinics, that offer 
diagnostic capabilities at lower costs and greater convenience than conventional 
laboratory testing. CLIA-waived clinics embody a shift in the healthcare landscape 
towards decentralization and higher accessibility of medical testing. The separation of 
unwanted cellular material is critical for the accuracy and reliability of many molecular 
diagnostics tools30, for example many blood tests require that plasma is separated from 
red blood cells prior to analysis. In commercial blood testing laboratories, centrifuges 
are almost exclusively employed to perform separation and is a key first step to facilitate 
accurate quantitative diagnostics31. However, the US Food and Drug Administration 
(FDA) classifies centrifuges as ‘moderately’ complex devices that are unsuitable for use 
in CLIA-waived environments32. This constraint has bottlenecked the translational 
ability of diagnostic technologies as centrifuges are unable to adapt for use at the point-
of-need and are becoming increasingly obsolete in a landscape that is seeking the further 
decentralization of testing services. 
Passive filtration membranes are a solution to perform cell separation at the point-of-
need and are often used with lateral flow assays33. Enabled by capillary action, the 
membranes operate on the principle of selectively preventing particles of a certain size 
from flowing through them. While inexpensive and easy to manufacture, the 
performance of these membranes is marred by inconsistencies in separation caused by 
clogged pores. Inconsistencies manifest themselves as variability in amount of plasma 
that is obtained during each run which deters the performance of quantitative lateral 
flow tests. Immunochemistry is sensitive to a variation in amount of sample that is used 
for analysis34,35. Additionally, the recovery rates of these methods is low36 (less than 
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30% of available plasma) which presents a barrier for analysis of analytes at low 
concentrations and sizes37.  
Several microfluidic approaches have been demonstrated in literature that achieve high 
levels of separation. These methods can be broadly classified into “active” and 
“passive” techniques38. Active techniques employ an external field (acoustic, electric or 
magnetic) that is used to align or immobilize the blood cells so as to enable the plasma 
to be separated in a continuous flow format. Passive methods typically separate the cells 
using hydrodynamic effects or separating pillars using cleverly designed and intricate 
microfluidic fabrication architecture39–41. While these techniques have been excellent 
demonstrative proof-of-concepts, they lack the ability to be commercialized as 
microfluidic fabrication is a highly involved and expensive process that lacks 
scalability42.  Further, in the case of active methods, the complex designs are often too 
cost-ineffective to integrate into existing microfluidic methods rendering them 
impractical for use at the point-of-need37. To address the high cost and lack of 
accessibility, many researchers have used common household items and toys like salad 
spinners and egg beaters to achieve plasma separation43–45.  These designs were cleverly 
engineered to simulate centrifugation but are not robust enough to operate in point-of-
need clinical settings. There is a need for low-cost technologies that can offer highly 
efficient blood-plasma separation at the point-of-need with high reliability and 
efficiency.  A ‘simple’ method would further enable present day diagnostics to transition 
for use at the point-of-need46–49 and enable the decentralization of blood testing services. 
In this paper we detail the design and principle of the High Efficiency Rapid Magnetic 
Erythrocyte Separator (dubbed H.E.R.M.E.S), a portable low-cost system that enables 
the separation and extraction of red blood cells from plasma within 2 minutes. 
H.E.R.M.E.S uses functionalized magnetic beads to capture and separate red blood cells 
and achieves near perfect separation, rivaling the efficiency of that of a commercial 
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centrifuge while using inexpensive raw materials. H.E.R.M.E.S employs a standalone 
protocol that does not require the use of any specialized lab equipment such as pipettes. 
We demonstrate the efficacy of H.E.R.M.E.S with the help of human samples, and 
further prove that H.E.R.M.E.S improves the performance of existing lateral flow assays 
in comparison to commercially available filtration membranes.    
 
3.3 Results 
 
3.3.1 H.E.R.M.E.S Device Design Landscape 
H.E.R.M.E.S has been designed with a specific intention of being easy-to-use. The 
process involves three main phases: capture, separation and extraction.  In order to 
obtain separated plasma, the user need only follow three steps (as outlined in Figure 6a), 
i) collect the sample (typically with a finger-stick) and load the sample in a test tube 
precoated with functionalized magnetic beads, ii) place sample in H.E.R.M.E.S and wait 
for 2 minutes, iii) remove sample and extract plasma using a capillary tube. Once the 
sample has been extracted, the sample can be used for further analysis or stored for 
future use. The portable benchtop device itself consists simple onboard electronics to 
enable automation (Figure 6d). H.E.R.M.E.S employs a small linear solenoid that 
actuates a magnetic field in a specific direction with respect to the sample to create a 
mixing effect. This ensures that the beads are able to capture the erythrocytes in the 
sample. The device occupies a small footprint and can be powered by any standard 
electrical outlet. Once the device is plugged in, the actuation starts automatically and 
proceeds for 90 seconds. After 90 seconds, the solenoid turns off and the magnetic beads 
are concentrated by the magnet on one side of the sample holder. The user then employs 
a small capillary tube to uptake the separated plasma. While the current iteration 
requires the use of an outlet, it can be easily re-engineered to include a portable battery 
pack instead. H.E.R.M.E.S was specifically designed to enable sample processing in 
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point-of-need settings and was designed for semi-autonomous operation to minimize 
the need for manual intervention by the user.  
Figure 6: a) Using H.E.R.M.E.S involves 3 simple steps i) collect and load the sample in a test tube 
precoated with functionalized magnetic beads, ii) place sample in H.E.R.M.E.S and wait for 90 seconds, 
iii) remove sample and extract plasma using a capillary tube. b) Size comparison of H.E.R.M.E.S against 
a standard laboratory centrifuge (Fisherbrand accuSpin Micro 17)  c) Side and top profile of the portable 
benchtop device respectively and d) exploded view of H.E.R.M.E.S showing its internal components. 
 
3.3.2 Magnetic bead capture of erythrocytes 
Magnetic bead based capture has been adopted several biological applications such as 
DNA extraction, peptidome assessment and immunocapture50–52. The technique is 
particularly useful for capturing a small amount of analyte as the beads can be 
concentrated to yield a higher limit of detection53. H.E.R.M.E.S tackles the opposite 
problem: a single microliter of human blood can contain up to 6 million blood cells. 
This resulted in a significant challenge as it was necessary to capture all the erythrocytes 
in the sample without the need for dilution. At first glance, it would appear a simple 
assessment of the binding capacity of the magnetic beads would be sufficient in order 
determine the minimum number of  
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beads required to capture all the blood cells in the sample. A “brute force” approach as 
such would be appropriate for separation but would suffer from a lack of scalability. 
Further, this approach would have a fragile dependence on the sample size with a cost-
scaling directly proportional to the number of cells that would need to be captured. In 
order to maintain a cost-effective scaling principle, H.E.R.M.E.S uses an aggregation 
agent that groups red blood cells together during the capture phase, thereby reducing 
the effective number of cells that need to be captured (See Figure 7). By aggregating 
the cells prior to the capture, we demonstrate an approximate 2000-fold increase in 
binding capacity of the beads using this aggregation agent. H.E.R.M.E.S is unique in 
comparison to previous works in literature that employ aggregation enhanced capture 
as it is performed in an easily accessible format that does not require specialized 
filtration paper or microfluidic setup54,55. Our estimations reveal that on average, one 
bead is able to capture up to 100 cells due to the aggregation effect. Approximately 5.4 
mg of blood cells are captured with close to a tenth of the amount of beads.  
 
Figure 7: a) Effect of aggregation of blood cells prior to capture and b) Separation of plasma from 
captured red blood cells with application of a magnetic field as seen under a microscope 
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3.3.3 Evaluation of H.ER.M.E.S using human samples 
We used H.E.R.M.E.S to process blood samples from 15 individuals and analyzed the 
plasma obtained after extraction (Table 1). We demonstrate an average purity greater 
than 99.9% (less than 20 cells/µL counted) and an average extraction  
time of 108 seconds to obtain 90% of the available plasma. H.E. R.M.E.S demonstrates 
a high efficiency to capture and separate red blood cells irrespective of blood type and 
hematocrit levels (See Appendix A). To further demonstrate the ability of aggregation 
to enhance the capture rate, we used H.E.R.M.E.S to separate erythrocytes in artificially 
spiked blood samples that have abnormally high hematocrit (Figure 8). We hypothesize 
that the aggregation effect scales non-linearly with an increase in the number of red 
blood cells. The high concentration of blood cells decreases the interaction space 
leading to effective binding in these samples. H.E.R.M.E.S can perform reliably with 
an increase in red blood cells and is able to obtain highly pure plasma regardless of the 
number of blood cells. Factoring in the cost of the aggregation agent and the beads, we 
expect H.E.R.M.E.S to cost less than $2 per separation test (See Appendix A).  
 
Table 1: Data collected from testing 15 human blood samples with varying ages, hematocrits and blood 
types. A starting volume of 40 µL was used for each test.  Samples were run in duplicate and the standard 
deviation is reported. Average volume of uncontaminated plasma obtained from centrifugation was 18.2 
µL. All samples were purified using 0.625mg of magnetic beads and 200µg of aggregation agent.  
 
 
 
 
Average Purity of Obtained Plasma 99.95 ± 0.05% 
Average Time for Extraction 108 ± 21 seconds 
Average Volume Obtained 17.2 ± 1.96 µL 
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Figure 8: Separation of Plasma from human samples with artificially high hematocrit values. Each 
sample was tested in duplicate and the standard deviation for each sample set is indicated with error bars 
(n=2). An average purity of 99.9% was obtained in these samples. 
 
3.3.4 Quantifying the effect of aggregation on performance 
Aggregation reduces the number of effective targets that need to be captured to obtain 
highly pure plasma. To understand the dependence of the aggregation capabilities on 
separation performance, we tested the cell capture rate with varying levels of 
aggregation agent. The cell capture rate was indirectly inferred by calculating the purity 
of the plasma obtained after separation. We then compared the purity of plasma obtained 
using different sample volumes to assess the scalability of the technique. As seen in 
figure 9, it can be noted that a concentration of about 3.5mg/mL of aggregation agent is 
sufficient to obtain plasma of high purity (greater than 99%). We also observe a non-
linear relationship wherein the binding capacity is amplified several-fold as the amount 
of agent is increased. We expect the curve to be pushed further out in the regime where 
the concentration of the aggregation agent is low. However, there exists a critical 
concentration that creates the level of aggregation necessary to obtain highly pure 
plasma (greater than 99%). In contrast, we also studied the effect of increasing the 
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number of magnetic beads on performance and noted that the amount of beads does not 
significantly affect the separation of performance.  
Figure 9: a) Plot showing the effect of the aggregation agent on performance of H.E.R.M.E.S. Three 
different sample volumes were used as noted in the legend. A non-linear relationship is observed between 
the amount of blood cells and the amount of aggregation agent required to capture them. An average of 
34 µL and 53 µL of total recovered plasma were obtained in the cases of samples tested using 80 and 120 
µL volumes.   Standard deviation for each sample is indicated with error bars. (n=2). The inset shows that 
the concentration of magnetic beads does not affect the performance significantly. b) Images of separated 
plasma at three different aggregation agent concentrations. A concentration of around 3.5mg/mL is 
optimal to obtain highly pure plasma.  
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3.3.5 Integration with existing diagnostic testing platforms 
We demonstrate the ability of H.E.R.M.E.S to augment the performance of present-day 
diagnostics by incorporating the technology with lateral flow test strips – a common 
diagnostic platform often implemented for use at the point-of-need. Ferritin lateral flow 
strips previously described by Srinivasan et al56 were tested using 10 human blood 
samples. We compared the performance of H.E.R.M.E.S against commercially 
available filtration paper (MDI). A calibration curve was built with a linear trendline fit 
to compare the performance of the two test cases (Figure 10). In general, we observed 
that H.E.R.M.E.S leveraged higher quantitative power from the regression model used 
in each of these cases. ROC curves were plotted using the Delong method27 and a 
difference in performance was established. Further, as seen in figure 5 a higher slope 
(46%) was noted for test strips that incorporated plasma obtained from H. E.R.M.E.S 
indicating greater quantitative ability across the concentration range of interest. More 
importantly, H.E.R.M.E.S was able to demonstrate a significantly reduced average 
coefficient of variation (6% vs 21%) further proving that it is capable of advancing the 
performance of point-of-need testing platforms.  
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Figure 10: a) Plot comparing the performance of plasma obtained from H.E.R.M.E.S and commercially 
available filtration paper. A starting volume of 40µL was used for each test and 15µL of plasma was used 
for the strips that were used with H.E.R.M.E.S. The pictures on the left and right side of the plot are 
images of test strips run using plasma obtained from H.E.R.M.E.S and filtration paper respectively. In 
general, we note a higher T/C ratio for all the samples that used H.E.R.M.E.S for separation. Further, we 
observe a higher coefficient of determination R2 and a sharper slope in the case of samples processed with 
H.E.R.M.E.S. The standard deviation of each sample (n=2) is indicated by error bars. b) Comparison of 
the mean coefficient of variations (CV = standard deviation/mean *100) between the two types of plasma. 
The CV of all samples from H.E.R.M.E.S was lower than 10%. c) Comparison of the ROC curves 
(generated using the Delong method). The a.u.c from samples purified by H.E.R.M.E.S was 1 and the 
a.u.c from filtered samples was 0.789. 
 
3.4 Discussion and Conclusion 
 
H.E.R.M.E.S leverages the elementary concept of magnetic separation to carry out a 
challenging process of separating unwanted cellular material from a sample. The 
method was specifically designed to be low-cost, rapid and minimally complex. The 
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system was designed to allow for maximal automation and minimal intervention from 
the user while maintaining a low-cost. These characteristics make H.E.R.M.E.S a 
promising alternative to the traditional lab centrifuge in settings where a centrifuge 
cannot operate, whether due to regulatory constraints or resource limitations. Further, 
while we validated H.E.R.M.E.S with a commonly available point-of-need testing 
platform (lateral flow tests), it is universal and can be used to simplify purification for 
virtually any diagnostic test that requires plasma or serum as an input. While there are 
a handful of sophisticated commercial platforms that are capable of performing 
immunoassay chemistry without the need for separating red blood cells, H.E.R.M.E.S 
will enable the use of standard diagnostic techniques in low-resource settings where 
other alternatives are not feasible. Further, the high recovery rate (>90% of available 
serum), the low time for recovery, the low cost and ease of use of the system make it 
superior to solutions that have been demonstrated in literature. 33,36,57 
H.E.R.M.E.S has the potential to impact the blood testing industry due to its ability to 
offer the separation efficiency of a centrifuge at a fraction of the time and cost. 
H.E.R.M.E.S seeks to facilitate the implementation of present-day diagnostic tools at 
the point-of-need by integrating into CLIA-waived testing environments where 
centrifuges are currently unable to operate. H.E.R.M.E.S can enable rapid front-end 
sample processing to help prevent loss of sample quality in these environments by 
ensuring that all red blood cells are removed prior to clinical chemistry testing. We 
envision H.E.R.M.E.S having immediate applicability in advancing molecular 
diagnostics such as PCR to the point-of-need as it can integrate easily into existing 
methods for translational PCR. Particularly, the isolation of white blood cells makes an 
interesting use case for infectious disease detection58,59 and genetic sequencing60. In 
addition to being highly scalable due to the low cost of raw materials that are involved 
in fabrication, H.E.R.M.E.S is able to perform highly efficient blood plasma separation 
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within 2 minutes at less than $2 per test and is suitable for use in resource-limited 
settings. While the current iteration of H.E.R.M.E.S is only capable of accommodating 
one sample, we envision that a future prototype will possess parallel sample processing 
capabilities as the underlying technique is highly scalable.  Further, the stand-alone 
system is easy to use and can be adopted by users irrespective of their prior medical 
training making the H.E.R.M.E.S a unique method to perform blood-plasma separation 
at the point-of-need.  
 
3.5 Materials and methods  
 
3.5.1 Preparing Magnetic beads:  
Magnetic beads (ProMag HP, Bangs Labs) suspended in a 50mM MES Buffer were 
conjugated to a Anti Red Blood Cell antibody (Rockland Antibodies) by incubating the 
sample in an end-over-end mixer for 12-15 hours. After conjugation, the supernatant 
was removed and replaced with a storage buffer (10mM Tris Buffer, pH 8, 0.05% 
Bovine Serum Albumin, 0.05% Proclin 300). The beads were stored at 4-8°C in liquid 
form and are stable up to several months. Prior to testing, 325 µg of beads and 200µg 
of antibody were loaded in a single PCR tube (Eppendorf) and dried in a vacuum 
centrifuge (Eppendorf Vacufuge 5301) for 30 minutes. The antibody is added separately 
to induce clumping of the red blood cells to reduce the number of effective targets 
during the capture process. Dried beads were then used for tests or stored at 4-8°C. The 
dried beads demonstrated a shelf life of up to three months when sealed in a dark 
container. 
 
3.5.2 H.E.R.M.E.S benchtop unit:  
A small portable benchtop unit was designed in Sledworks and printed using a Objet 
3D printer. The device itself consists of a microcontroller (Teensy 3.2, Sparkfun), a few 
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transistors and a 12V actuating solenoid (Adafruit Industries). Two circular neodymium 
magnets (K&J Magnetics) were mounted on a 3D printed holder and attached to the 
solenoid. The device also has a power input jack that can be connected to standard 12V, 
0.5A wall power supply.   
 
3.5.3 Analysis of Plasma:  
Upon separation of plasma from the red blood cells using H.E.R.M.E.S, a capillary tube 
(Microcaps, Drummond Scientific) was used to extract the serum from the sample and 
transferred into another test tube. Once transferred, the serum was diluted 5 times and 
mixed in a 1:1 ratio with trypan blue stain. Once stained, the serum was loaded into a 
disposable hemocytometer (C-Chip, Cyto Diagnostics) and cell counting was performed 
under a bright field microscope. The number of cells counted were then used to estimate 
the purity of the plasma obtained. 
 
3.5.4 High Hematocrit Samples:  
Blood samples with abnormal hematocrits were prepared with type O human red blood 
cells suspended in alsever’s solution (Innovative Research). The blood cells were spun 
down and concentrated in a centrifuge and resuspended to abnormally high hematocrit 
values (70,80 and 90%) 
 
3.5.5 Lateral Flow Test:  
Ferritin strips were manufactured similar to work mentioned in Srinivasan et al. We 
prepared two batches of test strips with blood filtration membranes (Type FR-1(0.35) 
MDI membrane technologies) used as a sample pad. The FR-1 is a passive forward 
flowing filtration membrane that has a thickness of 0.35 mm and capacity of 30 µL/cm2. 
10 human blood samples (Innovative Research) were then used for testing. For the strips 
that used the filtration membranes, a 3-minute incubation period was added at the 
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beginning of the test to allow the plasma to filter through the membrane. This was 
followed by the application of 40uL of running buffer to start the test. For the test cases 
that used plasma from H.E.R.M.E.S, the test was immediately started by using a 15µL 
capillary tube to apply the plasma onto the sample pad followed by application of 40µL 
of running buffer. We note that these test strips could also have been used as a dipstick 
format, wherein the sample pad is dipped in the sample holder to start the test. After 30 
minutes, the test strips were imaged using the TIDBIT (previously mentioned by Lu et 
al61) and a calibration curve was built using custom python code. Actual ferritin values 
were obtained using a SIEMENS Immulite1000 immunoassay analyzer.  
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CHAPTER 4 
 
cAST: CAPILLARY-BASED PLATFORM FOR REAL-TIME PHENOTYPIC 
ANTIMICROBIAL SUSCEPTIBILITY TESTING 
 
4.1 Abstract 
 
Antibiotic resistance is recognized as one of the greatest threats to public health. 
Antibiotic resistant pathogens affect nearly 2 million people a year in the US alone and 
creates an estimated $34B burden on the healthcare system. The rise in occurrence of 
resistant organisms can be attributed to a combination of over-prescription of antibiotics 
and a lack of accessible diagnostic methods. Delayed diagnosis is the primary reason 
for increased clinical risk and diagnostic methods that can enable a quick and accurate 
result are highly desirable to help enable effective treatment. This is particularly true for 
clinical situations at the point-of-care where access to state of- the art equipment is 
scarce. We present here cAST, a unique approach that offers accelerated assessment of 
antibiotic resistance in a low-cost and simple testing format. cAST delivers an expedited 
time to readout by means of colorimetric assessment of a resazurin dye that is incubated 
with the pathogen in a small capillary form factor. cAST was built using a combination 
of off-the-shelf and custom 3D printed parts, making it extremely suitable for use in 
resource-limited settings. We prove that growth of bacteria in cAST is approximately 
25% faster than in a conventional well microplate and further validate the diagnostic 
performance with 5 clinically relevant infectious organisms. We demonstrate that cAST 
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can deliver accurate AST results within 4-8 hours and discuss the potential for the 
underlying technology to be implemented into conventional optical AST assays.  
 
4.2 Introduction 
 
In recent years, the emergence and increasing occurrence of antimicrobial resistance 
(AMR) is a serious public health concern that places a substantial burden on the 
healthcare system.  Antibiotic-resistant infections are associated with longer hospital 
stays, poorer clinical outcomes, and increased healthcare costs 62.  The Center for 
Disease Control (CDC) estimates that more than two million antibiotic-resistant 
infections occur in the US each year, resulting in at least 23,000 deaths, $20 billion in 
excess direct healthcare costs, and $35 billion in lost productivity 63.  The threat of AMR 
is exacerbated by the over-prescription of broad-spectrum antibiotics as well as the lack 
of new antibiotics from the pharmaceutical industry 62.  The empirical prescription of 
antibiotics induces selective pressures that promote the development of antibiotic 
resistant organisms.  As a result, diagnostic methods that can eliminate diagnostic 
uncertainty and enable evidence-based treatment form one of the most effective ways 
to curb antibiotic misuse and in turn the development of resistant organisms 64. 
To facilitate the appropriate prescription of antibiotics, common methods of assessing 
the antimicrobial susceptibility of bacterial isolates include broth dilution, disk 
diffusion, and use of automated instrumentation 65,66.  In broth dilution, bacterial 
inoculums are cultured overnight in tubes of liquid growth medium supplemented with 
different concentrations of antibiotics.  Following incubation, visual inspection of the 
tubes for turbidity, which is evidence of bacterial growth, is conducted to determine the 
minimal inhibitory concentration (MIC).  Quantitative determination of MIC is one of 
the primary advantages of broth dilution, but the technique is limited by the relatively 
large quantities of reagents required.   In disk diffusion, bacterial inoculums are cultured 
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on an agar plate with paper antibiotic disks placed on the surface.  Following an 
incubation period of 16-24h, the zones of growth inhibition around each antibiotic disk 
is measured and compared to known criteria for a qualitative susceptibility assessment 
(susceptible, intermediate, or resistant).  Disk diffusion has the advantages of being 
simple and low-cost but is qualitative and open to subjective interpretation of results 67.  
In automated microdilution methods, incubation and optical detection systems are 
combined and used to detect bacterial growth in the presence of antibiotics in multi-well 
microdilution format, although manual preparation of inoculums is typically required 
beforehand 67.  While automated instrumentation can be leveraged to simplify workflow 
and enable real-time measurements, the high cost of the instruments and associated 
consumables limits their accessibility for use in point-of-care applications and resource-
limited settings.  Accessible antimicrobial susceptibility testing (AST) is crucial as 
evidence shows that each hour delay in proper antibiotic administration increases the 
risk of mortality in patients with severe sepsis 68. 
Many alternatives to existing AST methodologies have been developed 69.  Examples 
of genotypic and phenotypic methods include tests based on resistance gene detection 
70, microscopy 71,72, colorimetric detection 73,74, and microfluidics 75–78.  Because 
genotypic methods only determine the presence or absence of a resistance gene, 
phenotypic AST is needed to determine the actual susceptibility profile of an organism 
79.  In phenotypic methods, speed of growth is fundamentally limited by the replication 
speed of the target organism; however, the sensitivity of growth detection can be 
enhanced with the use of colorimetric indicators.  For instance, resazurin, a redox 
indicator that undergoes irreversible color change in the presence of metabolically 
active bacterial organisms, has been shown to increase sensitivity of microbial growth 
detection compared to turbidity alone 80.  Despite the number of innovations in this area, 
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the specialized training, instrumentation, and/or fabrication that many alternative AST 
techniques require have created barriers to clinical adoption. 
In this work, we developed a novel capillary-based Antimicrobial Susceptibility Testing 
(cAST), a platform composed of a mix of custom and off-the-shelf components 
combined to enable phenotypic susceptibility testing in real-time. Our platform employs 
metal capillary tubes along with a resazurin dye to enable accelerated detection of 
bacterial growth by means of spectral measurements of sample volumes that are 
significantly smaller than what is needed to achieve reliable measurements in 96/384 
well plates.  We demonstrate that our system can detect bacterial growth and determine 
antibiotic susceptibility for several clinically relevant organisms within 4-8 hours of 
incubation.  Our platform is an accessible alternative to conventional automated AST 
and its simplicity makes it well-suited for use in resource-limited settings.  
 
4.3 Materials and Methods 
 
4.3.1 Comparing growth in capillary tubes vs. microwell 
To examine the impact of incubation format on bacterial growth in small volumes, 
bacterial incubation inside capillary tubes was compared to incubation inside wells of a 
384-microwell plate.  Using the same dilution steps described in detail in the 
susceptibility testing section, Escherichia coli ATCC 25922 overnight culture was 
diluted to a starting concentration of 5×105 colony-forming units per milliliter (CFU/ml) 
in cation-adjusted Mueller-Hinton broth (CAMHB, Becton Dickinson) and 
supplemented with 10% v/v of three different colorimetric indicators separately: phenol 
red (MilliporeSigma), bromomethyl blue (MilliporeSigma), and resazurin (PrestoBlue, 
Thermo Fisher).  For all three colorimetric indicators, metabolically active bacteria 
induce color change in the media over time, which can be quantified through measuring 
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sample absorbance.  By testing three colorimetric indicators and two sample incubation 
formats, we wanted to determine which combination yields the fastest detection of 
growth.  15µl volumes of each dye-supplemented culture were loaded into multiple 
capillary tubes of size 65 mm × 0.0382 in. × 0.0276 in. (L × O.D. × I.D., Drummond 
Scientific) via capillary action and wells of a 384-microwell plate (VWR) via pipetting.  
The 15µl volume was selected to ensure even coating of the well bottoms for consistent 
absorbance measurements.  Loaded capillary tubes and the master microwell plate were 
incubated at 37°C.  In one-hour interval between hour 0 and hour 1, 30 min. intervals 
between hour 1 and hour 2, and 15 min. intervals between hour 2 and hour 4, sample 
absorbance in the 350nm – 650nm range with 1nm resolution was measured using a 
SpectraMax Plus 384 microplate reader.  For each measurement, capillary and 
microwell samples containing each of the three colorimetric indicators were transferred 
to a new 384-microwell plate in duplicate along with dye-supplemented CAMHB 
without bacteria as the negative controls.  The difference in peak absorbance (peak shift) 
between a test sample and negative control sample was used as a quantitative indicator 
of bacterial growth.  In a separate experiment, bacterial growth inside capillary tubes 
with different inner diameters 0.45mm, 0.70mm., and 0.76 mm) was quantified using 
the same spectroscopic approach.        
 
4.3.2 cAST platform design and operation 
The cAST platform consists of the following components: custom motor mount/sample 
holder, optical coupler, LED holder, and commercially available stepper motor, 
microcontroller, capillary tubes, and portable spectrometer. Custom device parts were 
designed in SolidWorks and 3D printed using an Objet 3D printer. The motor 
mount/sample holder houses a bipolar stepper motor (SparkFun Electronics) that drives 
the optical coupler during data acquisition as well as 1/16 in. stainless steel capillary 
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tubes (Supelco) that hold the samples.  The optical coupler enabled precise alignment 
of a 400um fiber-optic patch cable (Edmund Optics) with the capillary tubes.   The patch 
cable was connected to a portable spectrometer (Ocean Optics HR2000) that was used 
for spectral intensity measurements of samples.  The LED holder was fixed with 10 
high-power white LEDs (Lite-On Inc) that served as the light-source for measurements.  
A transistor array was soldered to the stepper motor to allow for precise control of the 
motor spindle.  An Arduino Uno microcontroller was connected to the transistor array 
and LEDs and programmed to automate spectral intensity measurement of the capillary 
tubes following a fixed time interval. 
We utilized steel capillary tubes of size 50 mm × 1.59mm. × 0.762 mm. (L × O.D. × 
I.D.) to hold the samples.  Alternatively, glass capillary tubes (Drummond Scientific) 
of similar size can also be used.  However, in this case the ends of the tubes must be 
coated with paint to prevent excess light from the LEDs leaking into the fiber-optic 
detector.  During sample loading, 4µl liquid culture droplets were individually pipetted 
onto a clean substrate and then loaded into the tubes via capillary action.  The capillary 
tubes were sterilized prior to loading through autoclaving.  Following loading, tubes 
were inserted into the sample holder in a configuration that allows light from the LEDs 
to pass through the sample and into the fiber-optic detector.  Since the volume capacity 
of the capillary tubes was higher than the sample volume of 4µl, the tubes were loaded 
with the fluid-filled side near the light-source as this configuration was determined to 
yield higher signal-to-noise ratios.  During susceptibility testing, the cAST platform was 
placed inside a benchtop incubator (Corning) set to 37°C.  A small portable humidifier 
was also placed inside the incubator to minimize sample drying during incubation.  
Every 30 minutes, spectral intensity measurements were automatically taken for each 
sample and the data were transferred and stored on a computer for processing using 
OceanView.  
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4.3.3 Susceptibility testing using cAST platform 
The cAST platform was used to test five different organisms: Escherichia coli ATCC 
25922, Enterobacter cloacae ATCC 13047, Acinetobacter baumannii ATCC BAA-
747, Pseudomonas aeruginosa ATCC 27853, and Escherichia coli K12 ER2267 
(kanamycin resistant).  To prepare inoculums for AST, bacteria strains were first 
streaked on Mueller-Hinton II agar plates (Becton Dickinson) and incubated overnight 
at 37°C.  For the kanamycin resistant E. coli K12 strain, the agar was supplemented with 
kanamycin (MilliporeSigma) at 50μg/ml.  Liquid cultures were then prepared by 
inoculating single colonies from the streak plates into cation-adjusted Mueller-Hinton 
broth (CAMHB, Becton Dickinson), followed by another overnight incubation at 37°C.  
To achieve the recommended starting inoculum concentration of 5×105 colony-forming 
units per milliliter (CFU/ml) for AST 81, the overnight culture was first diluted using 
CAMHB to a 0.5 McFarland standard, which represents a concentration of 
approximately 1×108 CFU/ml.  Using a spectrophotometer (VWR V-1200), the 
OD625nm absorbance corresponding to a 0.5 McFarland standard was verified to be in 
the range of 0.08 – 0.13 81.  The diluted culture was next additionally diluted 1:100 in 
CAMHB media, split into subcultures, and supplemented with varying concentrations 
of antibiotics and a resazurin (PrestoBlue, Thermo Fisher) solution (10% v/v final) to 
reach an approximate starting inoculum concentration of 5×105 CFU/ml.  Resazurin is 
a redox indicator that is reduced by metabolically active cells into resorufin, leading to 
significant colorimetric and fluorescent changes in the culture media which can be 
measured to gauge bacterial growth 80.  The aminoglycoside gentamicin was selected to 
be the target antibiotic for susceptibility testing since it is classified by the Clinical & 
Laboratory Standards Institute (CLSI) as a Group A (appropriate for inclusion in 
primary AST panel) antimicrobial agent for all five of the organisms used in this study 
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82.  The E. coli K12 strain was additionally tested with kanamycin to characterize its 
increased resistance to the antibiotic.  Antibiotic concentrations used for testing were 
selected based on the susceptible, intermediate, and resistant breakpoints published by 
CLSI 82.  For testing, 4µl culture samples were loaded into capillaries and subsequently 
into the cAST platform for automated spectral intensity measurements every 30 min. 
over a period of 6 – 8 hours.  Positive control samples consisted of bacteria inoculums 
in CAMHB without the addition of antibiotics and negative control samples consisted 
of bacteria inoculums in CAMHB with the addition of high concentrations of antibiotics 
(>3× CLSI resistant breakpoint concentration).  Negative control samples were 
formulated in this manner to account for any interactions between non-viable/non-
proliferating bacteria and resazurin.   
 
4.3.4 Data analysis 
Spectral data captured by the cAST platform were imported into MATLAB for analysis.  
Lowess regression smoothing was first applied to smooth spectral data followed by 
algorithmic identification of peaks in the spectral data.  Resazurin’s peak absorbance is 
around 600nm and this peak absorbance exhibits blueshift upon conversion of the dye 
into resorufin by metabolically active bacteria.  A similar blueshift can be observed in 
the spectral intensity profile upon dye reduction.  The difference in peak intensity (peak 
shift) between a test sample and negative control sample was used as a quantitative 
indicator of bacterial growth.  Time to growth detection was determined using a peak 
shift threshold as non-susceptible and positive control samples exhibited peak shifts 
>30nm upon reduction of resazurin.    
 
4.3.5 Susceptibility verification using broth dilution 
To verify concentration-dependent susceptibility determined using the cAST platform, 
broth macrodilution was concurrently conducted as a secondary method to assess 
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susceptibility.  Using the same inoculum preparation steps outlined above, 2ml liquid 
cultures with approximate starting inoculum concentration of 5×105 CFU/ml were 
supplemented with the same antibiotic concentrations as the capillary samples (without 
resazurin) and subsequently incubated overnight in a shaking incubator at 37°C.  
Following incubation, susceptibility was visually determined based on whether turbidity 
was observed.     
 
4.4 Results 
 
4.4.1 cAST platform  
cAST consists of a combination of off-the-shelf components and 3D printed parts, as 
seen in Figure 11. Key components include a stepper motor, fiber-optic cable, portable 
spectrometer, light source, and 3D-printed parts designed to hold components in 
alignment for optical measurements.  The underlying principle of operation of cAST is 
simple – light incident on one end of the capillary tube passes through the sample and 
is then captured by the fiber-optic cable, with the opaque capillary tube serving as an 
optical waveguide.  The fiber-optic cable is coupled to a portable spectrometer that 
measures the spectral intensity profile of the captured light, which can be monitored for 
relative changes that are indicative of bacterial growth and antibiotic susceptibility.  
With the help of an onboard microcontroller, measurements are automated for multiple 
samples at an adjustable time interval.   
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Figure 11.  Overview of cAST platform.  (A) Realistic render of cAST experimental setup.  During 
susceptibility testing, capillary tubes containing bacteria samples are loaded into the cAST device, which 
is then placed inside a benchtop incubator.  A fiber-optic cable connects the cAST device to an external 
spectrometer, which together with a microcontroller enables automated spectral intensity measurements.  
(B) Dimensions of the cAST device.  (C) Exploded view of the integral components of the system.  The 
sample holder was designed to allow light from the LEDs to pass through the capillary tube sample and 
into the fiber-optic detector.  During data acquisition, the positioning of the fiber-optic cable is controlled 
by the stepper motor via rotation of the optical coupler. 
The advantages of the cAST platform are three-fold: 1) the system enables accelerated 
detection of antimicrobial resistance, 2) the system is automated which simplifies 
workflow when working with multiple samples, and 3) the system facilitates non-
contact optical interrogation of small sample volumes (<5 μL, and 3) the system enables 
non-contact optical interrogation of small sample volumes (< 5μl).  The cylindrical form 
factor of a capillary tube maximizes the optical path length which facilitates optical 
measurements without requiring optical cavities 83 or traditional microscopy 
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instruments for readout 76,84, components that are typically required in microfluidic 
systems which ultimately increase fabrication and operational complexity.  In addition 
to these advantages, the entire cAST system has a small footprint and is built using 
inexpensive parts making it suitable for use in resource-limited settings.  
 
4.4.2 Bacterial growth in capillary tubes 
Prior to susceptibility testing with the cAST platform, we compared detection of 
bacterial growth in capillary tube versus microwell using three different colorimetric 
indicators: phenol red, bromomethyl blue, and resazurin.  By testing three colorimetric 
indicators, we wanted to first examine how incubation inside the capillary tube form 
factor affects bacterial growth and subsequently determine which indicator yields the 
fastest detection of growth.  For all three colorimetric indicators, metabolically active 
bacteria induce color change in the media over time, which can be quantified through 
spectral measurements.  Phenol red and bromomethyl blue are colorimetric pH 
indicators that change color in response to the accumulation of bacterial metabolic 
byproducts such as organic acids.  Resazurin is a redox indicator that changes color 
upon reduction into resorufin by metabolically active cells 80.  Using the test organism 
E. coli diluted to approximately 5×105 CFU/ml starting concentration, we loaded 15µl 
volumes of dye-supplemented cultures into capillary tubes and a 384-microwell plate 
and incubated the samples at 37°C.  Sample color change over time was quantified by 
measuring sample absorbance in the 350nm – 650nm range using a microplate reader.  
Capillary samples were dispensed into a microplate at time of measurement to enable 
use of the plate reader.  The difference in peak absorbance (peak shift) between a test 
sample and negative control sample (no bacteria) was used as a quantitative indicator 
of bacterial growth.  As shown in Fig. 12A, incubation inside the capillary form factor 
accelerated growth detection relative to incubation inside microwell and amongst the 
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three colorimetric indicators tested, resazurin yielded the fastest detection of growth.  In 
fact, resazurin in the capillary form factor yielded a time to growth detection that was 
45 minutes faster than resazurin in the microwell format. 
Using the same spectral measurement approach, we next investigated the impact of 
capillary tube inner diameter size on bacterial growth and time to growth detection.  E. 
coli inoculated media supplemented with resazurin, with 5×105 CFU/ml approximate 
starting concentration, was incubated inside capillary tubes with three different inner 
diameters (0.45mm, 0.70mm., and 0.76 mm.) and incubated at 37°C.  Sample color 
change over time, corresponding to bacterial growth, was quantified by measuring 
sample absorbance in the 350nm – 650nm range.  Because of the drastic wavelength 
shift of resazurin reduction observed in the previous experiment (Fig. 12A), time to 
growth detection was determined as the timepoint at which a wavelength shift of greater 
than 25nm was detected.  As shown in Fig. 12B, an inversely proportional relationship 
was observed between capillary tube inner diameter and time to growth detection. 
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Figure 12.  Comparison of E. coli growth in capillary tube and microwell.  (A) Comparison of detection 
of bacterial growth in capillary tubes and microwell using three different colorimetric indicators: phenol 
red, bromomethyl blue, and resazurin.  Bacterial metabolism induced color change in the media was 
tracked over time by measuring sample absorbance in the 350nm – 650nm range.  The difference in peak 
absorbance (peak wavelength shift) between a test sample and negative control sample (dye-
supplemented media without bacteria) was used as a quantitative indicator of bacterial growth.  Incubation 
inside capillary tubes with the dye resazurin was observed to yield the fastest time to growth detection.  
Error-bars denote one standard deviation (n=3).  (B) Impact of capillary tube inner diameter on time to 
growth detection.  Inoculated media supplemented with resazurin was incubated inside capillary tubes 
with different inner diameters, represented by Φ1,Φ2 and Φ3.  Bacterial growth was tracked over time by 
measuring absorbance and determining peak wavelength shift relative to a negative control sample.  Time 
to detection was determined as the timepoint at which a wavelength shift of greater than 25nm was 
detected.  An inversely proportional relationship was observed between capillary tube inner diameter and 
time to growth detection. 
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4.4.3 cAST enabled susceptibility testing 
The cAST platform was designed to capitalize on the phenomenon of faster observed 
growth of bacteria in capillary format in the context of susceptibility testing.  We 
hypothesize that faster growth, evidenced by faster reduction of resazurin, is due to 
optimal bacteria and nutrient distribution in the capillary format.  As shown in the 
comparison in Fig. 13C & D, we hypothesize that the small length scale of the capillary 
tube leads to a uniform distribution and diffusion of bacteria within the sample matrix 
which likely maximizes access to nutrients and optimizes growth.  Similar accelerated 
growth has been observed for bacterial incubation inside microfluidic microchannels 
with large surface area-to-volume ratios 78.  
As shown in Fig. 13A, cAST enabled susceptibility testing is based on the principle that 
bacterial inhibition by antibiotics will limit the reduction of resazurin into resorufin.  On 
the other hand, non-susceptible/resistant bacteria will proliferate and reduce resazurin 
into resorufin, thereby inducing significant changes in the color of the sample media 
over time.  Instead of a spectrophotometer, a portable spectrometer was used to monitor 
color change due to its smaller footprint and the ability to make measurements in-
incubator in real-time without interrupting sample incubation.  The spectral intensity 
profile change corresponding to the reduction of resazurin is shown in Fig. 13B.     
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Figure 13.  Antibiotic susceptibility testing in capillary format.  (A) Schematic of cAST setup illustrating 
use of resazurin as colorimetric indicator for phenotypic detection of bacterial growth.  For bacteria 
uninhibited by a particular antibiotic concentration, subsequent proliferation over time leads to the 
reduction of resazurin into resorufin, which is characterized by a significant change in the color of the 
sample media.  (B) Sample color change over time can be quantified through spectral measurements – 
either through measuring sample absorbance (using benchtop spectrophotometer) or through measuring 
the spectral intensity profile of light (using portable spectrometer as part of cAST platform) that pass 
through the sample.  Changes in the peak absorbance/intensity wavelength of the sample relative to a 
negative control provide a quantitative indicator of bacterial growth.  (C) and (D) Hypothesized advantage 
of sample incubation inside capillary tubes compared to other form factors.  In a large culture tube, the 
bacteria settle at the bottom as they grow and create an uneven growth environment. The relatively small 
inner diameter of the capillary, however, leads to a uniform distribution of bacteria within the sample 
matrix which maximizes access to nutrients and optimizes growth.  
 
4.4.4 Susceptibility testing of clinically relevant organisms 
The cAST platform was used to test five different organisms: Escherichia coli ATCC 
25922, Enterobacter cloacae ATCC 13047, Acinetobacter baumannii ATCC BAA-
747, Pseudomonas aeruginosa ATCC 27853, and Escherichia coli K12 ER2267 
(kanamycin resistant).  These opportunistic pathogens are among the prominent causes 
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of hospital-acquired infections and are frequently drug resistant 85.  We tested each 
organism’s susceptibility to the aminoglycoside gentamicin as this antibiotic is 
classified by the Clinical & Laboratory Standards Institute (CLSI) as a Group A 
(appropriate for inclusion in primary AST panel) antimicrobial agent against all five of 
the selected organisms 82.  The antibiotic concentrations we tested (1, 2, 4, and 50μg/ml) 
were selected taking into consideration the susceptible, intermediate, and resistant 
breakpoint concentrations published by CLSI.  The E. coli K12 strain was additionally 
tested with kanamycin (50, and 100μg/ml) to characterize its increased resistance to the 
antibiotic (Fig. 14A).  For each organism, we collected 6-8 hours of data using the cAST 
platform and the susceptibility results are shown in Fig. 4C.  Due to resazurin’s high 
spectral change upon reduction, the time point at which growth was detected can be 
determined through thresholding either spectral wavelength shift data or the associated 
slope data (Fig. 14B).  As expected for a phenotypic susceptibility testing technique, a 
strong positive correlation was observed between time to growth detection and organism 
doubling time (Fig. 14D).  Susceptibility results are summarized in Fig. 14E and 
individual data for each organism is noted in Appendix B.  cAST-enabled susceptibility 
results were verified against broth macrodilution, which showed unanimous agreement 
but required significantly longer incubation times.  
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Figure 14.  Multi-organism susceptibility testing data from cAST platform.  (A) Peak intensity 
wavelength shift over time for a kanamycin resistant E. coli strain.  The difference in spectral peak 
intensity (wavelength shift) between a test sample and negative control sample provides a quantitative 
indicator of bacterial growth.  The E. coli strain was tested with gentamicin (CLSI Group A antimicrobial 
agent) as well as kanamycin to characterize its increased resistance.  For a non-inhibiting antibiotic 
concentration, bacterial proliferation induced reduction of resazurin led to significant changes in the 
sample spectral intensity profile, as evidenced by drastic increases in peak wavelength shift.  Error-bars 
denote one standard deviation.  (B) Instantaneous slopes of peak intensity wavelength shift data.  (C) 
Antibiotic susceptibility data for five organisms: E. coli, E. cloacae, A. baumannii, P. aeruginosa, and a 
kanamycin resistant E. coli strain. The markers denote the time at which wavelength shift/slope exceeded 
a threshold, representing detection of organism growth.  The letter C represents the positive control group 
and the numbers denote antibiotic concentrations in µg/ml.  Gentamicin is represented by a square marker 
and kanamycin is represented by a triangular marker.  (D) Relationship between time to detection and 
organism doubling time.  (E)  Summary of AST results.  Susceptibility results were verified through broth 
macrodilution. 
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4.5 Discussion 
 
It is estimated that for patients with septic shock, every hour that goes by without 
appropriate antibiotic administration results in a 7.6% drop in survival rate 68.  In time 
sensitive situations, rapid AST techniques are crucial for expediting the administration 
of effective antibiotic therapy.  In this work, we demonstrated a novel rapid AST 
technique based on optical interrogation of organisms incubated inside a capillary tube 
form factor – which was empirically determined to accelerate time to growth detection 
and readout.  In particular, we were first able to demonstrate off-device that incubation 
in the capillary form factor yielded an approximately 25% faster readout compared to 
incubation in the microwell format, which is commonly used in microdilution AST 
methods.  Next, we demonstrated development of the cAST platform, a robust device 
setup that leverages 3D-printed and off-the-shelf components to enable automated 
optical measurements of samples housed in capillary format.  With the use of a resazurin 
redox indicator, we were able to demonstrate reliable AST results, for five different 
clinically relevant organisms within 4-8 hours, making it comparable in performance to 
microfluidic approaches demonstrated in literature (14-17). However, the simplicity of 
the testing setup, the ease of operation and the small footprint of the device make cAST 
a superior platform for use in resource-limited and translational settings.   
The cAST system offers several advantages relative to other AST methods.  Firstly, the 
low sample volume requirement (<5µl) limits reagent consumption and is conducive to 
minimizing the number of pre-AST incubation steps needed to scale up organism 
concentration.  For instance, AST can potentially be directly conducted using an 
inoculum from patient sample or streak plate.  Secondly, the platform utilizes 
commercially available capillary tubes, which are reusable following sterilization and 
are of lower fabrication and operational complexity compared to small volume sample-
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holding consumables used in microfluidic systems 75–78.  Thirdly, the small footprint 
and portability of the platform makes it amenable for use in point-of-care settings.  
The primary innovation of our work revolves around the discovery that bacterial 
incubation in the capillary form factor appears to enhance the growth rate, as evidenced 
by faster reduction of resazurin relative to bacterial incubation in microwells.  We 
hypothesize that this phenomenon is due to two possible reasons: 1) capillary forces 
within the tube induce a uniform distribution of bacteria and nutrients that optimizes 
growth or 2) bacterial confinement within small diameter capillary tubes facilitates 
nutrient-seeking chemotaxis behavior that promotes growth 86,87.  It is interesting to note 
the inverse correlation we observed between tube inner diameter and time to growth 
detection.  Smaller inner diameter tubes further accelerated growth, possibly as a result 
of greater internal capillary forces.  In the context of optical measurements, however, 
decreasing the tube inner diameter comes at the cost of reducing signal output.  For this 
reason, the bulk of our experiments were conducted using tubes with 0.76 mm inner 
diameter, which provided an optimal balance between accelerated growth and optical 
signal intensity. 
To further improve user-friendliness of the cAST platform, antibiotics and resazurin can 
be lyophilized directly inside capillary tubes – thereby simplifying the workflow and 
reducing the number of manual pipetting/dilution steps needed.  Through this approach, 
tubes can be pre-loaded with different antibiotics at varying concentrations and all that 
is needed to initiate testing would be rehydration of the lyophilized components with 
inoculated culture media.  A detachable sample holder with a circular mesh pattern can 
additionally be developed to increase the number of samples that can be tested in 
parallel, thereby increasing multiplexing potential.  As the spectrometer is the most 
expensive component of the current system, we envision a less expensive system can be 
achieved by replacing the spectrometer with a photodiode and optical filter set at the 
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appropriate wavelength to detect reduction of resazurin.  The addition of internal heating 
capabilities to the system will enable incubator-free AST, further improving portability 
and decreasing the infrastructure required for susceptibility testing.  The reduction of 
resazurin into resorufin induces both fluorescent and colorimetric changes in the culture 
media.  The addition of fluorescence detection to the cAST platform can increase the 
sensitivity of growth detection but comes with the tradeoffs of increased cost and 
complexity.    
In summary, we developed a capillary-based platform for rapid phenotypic 
antimicrobial susceptibility testing.  Our platform was designed to take advantage of the 
phenomenon that bacterial incubation inside capillary tubes enhanced growth, which in 
turn can be leveraged for faster susceptibility testing.  We demonstrated that our system 
was able to detect bacterial growth and determine antibiotic susceptibility for several 
clinically relevant organisms within 4-8 hours of incubation.  The cAST platform is an 
accessible alternative to conventional rapid AST methods and its simplicity makes it 
well-suited for use in resource-limited settings. 
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CHAPTER FIVE 
 
CONCLUSIONS AND FUTURE DIRECTIONS 
5.1 Engineering Biomedical Technologies for the developing world 
 
Point-of-care testing presents a suitable theme for the development of diagnostic tests 
of the present and future. In chapters 2 through 4 of this dissertation, I detail the 
development of new and unique biomedical technologies that are aimed at translating 
conventional laboratory testing from the benchtop to the bedside. While each of the 
technologies is centered around a tackling a different biomedical challenge, the 
underlying theme is the same: engineering technologies that are appropriate for use at 
the point-of-care and by extension, in resource-limited settings.  
In chapter 2, I highlight a novel method for assessing Vitamin D deficiency in human 
finger-stick blood with the help of a rapid diagnostic test. Vitamin D is notoriously 
difficult to detect even with conventional laboratory equipment as the protocols for 
testing involve laborious and time-consuming processing steps. With the help of the 
Nutriphone platform, we were able to demonstrate a quick and easy alternative to 
perform quantitative Vitamin D detection, with the help of a unique elution buffer that 
denatures the binding proteins in situ. This allows for a quantitative test to be conducted 
within 30 minutes with only a few drops of blood. This method could serve as a platform 
to perform large-scale nutritional screening in developing countries and is a promising 
step towards the development of personalized medical devices for the purpose of 
nutritional deficiency assessment.  
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In chapter 3, I discuss H.E.R.M.E.S, a unique sample processing technology that can 
help bridge the gap in demand and access to decentralized blood testing. H.E.R.M.E.S 
uses a novel magnetic bead-based approach to achieve the separation of blood from 
plasma in small volumes of sample. The separation is highly efficient and can be 
achieved in under 2 minutes at less than $2 per test by using a simple and portable 
benchtop device. This device is easy to use and requires minimal user intervention. 
H.E.R.M.E.S was designed to help improve the performance of existing rapid diagnostic 
tests, like the Vitamin D rapid diagnostic test mentioned in chapter 2. However, the 
scope of application extends beyond POC tests and is virtually compatible with any 
blood-based diagnostic test. Therefore, we strongly believe H.E.R.M.E.S can help usher 
in a new generation of blood-based diagnostic tests that were previously difficult to 
incorporate at the point of the care because of the requirement of centrifugation. 
H.E.R.M.E.S also has the potential to revolutionize molecular testing at the point of care 
and help bring highly accurate assays like PCR to the bedside.  
In chapter 4, I detail our initial efforts in the development of a platform for the 
accelerated assessment of antimicrobial resistance of bacterial organisms. cAST uses a 
unique capillary form factor, a resazurin dye and a portable spectrophotometer to give 
high resolution, real time viability information on bacterial organisms. We 
demonstrated that the simple act of incubating a bacterial organism in a capillary form 
factor speeds up the growth process by approximately 25% in comparison to a 
traditional well plate. We also prove the validity of cAST with the help of five clinical 
organisms and were able to demonstrate that cAST can provide accurate AST results 
within 4-8 hours of bacterial growth. cAST offers similar diagnostic performance to that 
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of other works in literature in a simple, easy to use setup that does not require specialized 
equipment. Further, the setup, composed entirely of off-the-shelf-parts and 3D printed 
units, is extremely suitable for use at the point of care and in resource limited settings. 
The underlying technology of cAST makes it useful for currently existing diagnostic 
tools as the primary innovation is universally applicable to most optical detection 
methods. Future work on this project will include the possibility of designing a refined 
version of cAST that uses simple electrical components like a photodiode to make the 
necessary measurements. For resource-limited settings, cAST can be implemented as a 
qualitative assay with the help of clear glass capillaries. In this use-case, the resistance 
can be directly inferred by visual inspection of a color change, thereby further 
eliminating the need for any specialized equipment.  
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APPENDICES 
APPENDIX A: SUPPLEMENTAL DATA FOR H.E.R.M.E.S 
 
Table A1: Demographic Information of samples used for human trial. Abbreviations: Caucasian (Cauc), 
African American (Af Am), Hispanic (Hisp). 
 
 
Table A2: Cost breakdown of raw materials for each test. 
 
Raw material Cost per test ($) 
Magnetic beads 0.55 
Aggregation Agent 1.3 
Conjugation Reagents 0.135 
Total Cost  1.985 
 
 
 
 
Sample # Ethnicity Age Gender Hematocrit % Blood type 
1 Cauc 49 M 56 O+ 
2 Af Am 54 M 55 A+ 
3 Cauc 48 M 45 O- 
4 Hisp 33 M 53 A+ 
5 Cauc 46 M 47 A- 
6 Cauc 41 M 48 A- 
7 Af Am 20 M 53 A+ 
8 Af Am 51 M 47 B+ 
9 Hisp 51 M 47 O- 
10 Hisp 45 M 48 A+ 
11 Cauc 55 F 52 O- 
12 Af Am 31 F 46 O- 
13 Cauc 39 F 57 O- 
14 Cauc 36 F 53 O- 
15 Hisp 58 F 42 B- 
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APPENDIX B: SUPPLEMENTAL DATA FOR cAST 
 
 
Figure B1: Real-time wavelength shift and slope data for A) and B) P.aeruginosa and 
C) and D) A.baumannii 
 
Figure B2: Real-time wavelength shift and slope data for A) and B) E.cloacae and C) 
and D) E.coli 
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